Patents by Inventor Andreas Haupt

Andreas Haupt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190135777
    Abstract: The present invention relates to quinoline compounds of formula I wherein the variables are defined as in the claims and the description. The invention further relates to a pharmaceutical composition containing such compounds, to their use as modulators of the 5-HT6 receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of the 5-HT6 receptor, and to methods for preventing or treating conditions and disorders which respond to the modulation of the 5-HT6 receptor.
    Type: Application
    Filed: December 21, 2018
    Publication date: May 9, 2019
    Inventors: Hervé GENESTE, Andreas HAUPT, Frauke POHLKI, Ana Lucia RELO, Liliane UNGER, Karsten WICKE
  • Publication number: 20190071443
    Abstract: The present invention relates to tricyclic quinoline and quinoxaline derivatives, to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HT2C receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-HT2C receptor, and to a method for preventing or treating conditions and disorders which respond to the modulation of 5-HT2C receptor.
    Type: Application
    Filed: November 2, 2018
    Publication date: March 7, 2019
    Inventors: Hannes Koolman, Wilfried Braje, Helmut Mack, Andreas Haupt, Ana Lucia Relo, Karla Drescher, Margaretha Henrica Maria Bakker, Viktor Lakics, Carolin Hoft, Ruxu Xu, Xiaona Zhao
  • Publication number: 20190062305
    Abstract: The present invention relates to pyridyl or pyrazinyl compounds carrying a methyl-bound N-amide moiety derived from an ?-amino acid of formula I where the variables are as defined in the claims and the description. The invention further relates to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HT2C receptor, and to their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of the 5-HT2C receptor.
    Type: Application
    Filed: September 21, 2016
    Publication date: February 28, 2019
    Inventors: Gisela BACKFISCH, Margaretha BAKKER, Günter BLAICH, Wilfried BRAJE, Karla DRESCHER, Thomas ERHARD, Andreas HAUPT, Carolin HOFT, Andreas KLING, Viktor LAKICS, Helmut MACK, Frank OELLIEN, Raimund PETER, Frauke POHLKI, Ana Lucia RELO
  • Publication number: 20190048007
    Abstract: The present invention relates to tricyclic quinoline and quinoxaline derivatives, to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HT2C receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-HT2C receptor, and to a method for preventing or treating conditions and disorders which respond to the modulation of 5-HT2C receptor.
    Type: Application
    Filed: June 8, 2018
    Publication date: February 14, 2019
    Inventors: Hannes Koolman, Wilfried Braje, Helmut Mack, Andreas Haupt, Ana Lucia Relo, Karla Drescher, Margaretha Henrica Maria Bakker, Viktor Lakics, Carolin Hoft
  • Patent number: 10160744
    Abstract: The present invention relates to quinoline compounds of formula I wherein the variables are defined as in the claims and the description. The invention further relates to a pharmaceutical composition containing such compounds, to their use as modulators of the 5-HT6 receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of the 5-HT6 receptor, and to methods for preventing or treating conditions and disorders which respond to the modulation of the 5-HT6 receptor.
    Type: Grant
    Filed: March 14, 2017
    Date of Patent: December 25, 2018
    Assignee: ABBVIE DEUTSCHLAND GMBH & CO. KG
    Inventors: Hervé Geneste, Andreas Haupt, Frauke Pohlki, Ana Lucia Relo, Liliane Unger, Karsten Wicke
  • Publication number: 20180339996
    Abstract: The present invention relates to compound of formula (I) (I) wherein the variables are as defined in the claims and the description. The invention further relates to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HT2C receptor, to their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-HT2C receptor, and to methods for preventing or treating conditions and disorders which respond to the modulation of 5-HT2C receptor.
    Type: Application
    Filed: November 24, 2016
    Publication date: November 29, 2018
    Inventors: Gisela BACKFISCH, Margaretha Henrica Maria BAKKER, Günter BLAICH, Wilfried BRAJE, Karla DRESCHER, Thomas ERHARD, Andreas HAUPT, Carolin HOFT, Viktor LAKICS, Helmut MACK, Frank OELLIEN, Raimund PETER, Ana Lucia RELO
  • Patent number: 10118926
    Abstract: The present invention relates to tricyclic quinoline and quinoxaline derivatives, to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HT2C receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-HT2C receptor, and to a method for preventing or treating conditions and disorders which respond to the modulation of 5-HT2C receptor.
    Type: Grant
    Filed: September 13, 2013
    Date of Patent: November 6, 2018
    Assignees: ABBVIE DEUTSCHLAND GMBH & CO. KG, ABBVIE INC.
    Inventors: Hannes Koolman, Wilfried Braje, Helmut Mack, Andreas Haupt, Ana Lucia Relo, Karla Drescher, Margaretha Henrica Maria Bakker, Viktor Lakics, Carolin Hoft, Ruxu Xu, Xiaona Zhao
  • Patent number: 9994568
    Abstract: The present invention relates to tricyclic quinoline and quinoxaline derivatives, to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HT2C receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-HT2C receptor, and to a method for preventing or treating conditions and disorders which respond to the modulation of 5-HT2C receptor.
    Type: Grant
    Filed: September 29, 2015
    Date of Patent: June 12, 2018
    Assignee: ABBVIE DEUTSCHLAND GMBH & CO. KG
    Inventors: Hannes Koolman, Wilfried Braje, Helmut Mack, Andreas Haupt, Ana Lucia Relo, Karla Drescher, Margaretha Henrica Maria Bakker, Viktor Lakics, Carolin Hoft
  • Publication number: 20170260158
    Abstract: The present invention relates to quinoline compounds of formula I wherein the variables are defined as in the claims and the description. The invention further relates to a pharmaceutical composition containing such compounds, to their use as modulators of the 5-HT6 receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of the 5-HT6 receptor, and to methods for preventing or treating conditions and disorders which respond to the modulation of the 5-HT6 receptor.
    Type: Application
    Filed: March 14, 2017
    Publication date: September 14, 2017
    Inventors: Hervé GENESTE, Andreas HAUPT, Frauke POHLKI, Ana Lucia RELO, Liliane UNGER, Karsten WICKE
  • Publication number: 20170158693
    Abstract: The present invention relates to tricyclic hexahydrodiazepinoquinolines carrying a cyclic substituent, to a method for producing them, to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HT2C receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-HT2C receptor, to a method for preventing or treating conditions and disorders which respond to the modulation of 5-HT2C receptor, and processes for preparing such compounds and compositions.
    Type: Application
    Filed: February 17, 2017
    Publication date: June 8, 2017
    Inventors: Gisela BACKFISCH, Margaretha Henrica Maria BAKKER, Günter BLAICH, Wilfried BRAJE, Karla DRESCHER, Thomas ERHARD, Andreas HAUPT, Hannes KOOLMAN, Viktor LAKICS, Anna LINSENMEIER, Helmut MACK, Raimund PETER, Ana Lucia RELO, Xiaona ZHAO, Jincheng WANG
  • Publication number: 20170112851
    Abstract: The present invention relates to tricyclic hexahydrodiazepinoquinolines carrying a substituted alkyl radical, to a method for producing them, to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HT2C receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-HT2C receptor, to a method for preventing or treating conditions and disorders which respond to the modulation of 5-HT2C receptor, and processes for preparing such compounds and compositions.
    Type: Application
    Filed: January 4, 2017
    Publication date: April 27, 2017
    Inventors: Gisela BACKFISCH, Margaretha Henrica Maria BAKKER, Günter BLAICH, Wilfried BRAJE, Karla DRESCHER, Thomas ERHARD, Andreas HAUPT, Viktor LAKICS, Anna LINSENMEIER, Helmut MACK, Raimund PETER, Ana Lucia RELO, Lynette SMITH
  • Patent number: 9573950
    Abstract: The present invention relates to compound of formula (I) as tricyclic hexahydrodiazepinoquinolines carrying a cyclic substituent, useful for modulating the 5-HT2C receptor and preventing and/or treating conditions and disorders that respond to the modulation of the 5-HT2C receptor. The present invention also relates to methods for producing compounds of formula (I), pharmaceutical compositions containing such compounds, and methods for preventing or treating conditions and disorders that respond to the modulation of the 5-HT2C receptor by administering compounds of formula (1) or pharmaceutical compositions thereof.
    Type: Grant
    Filed: March 13, 2015
    Date of Patent: February 21, 2017
    Assignee: AbbVie Deutschland GmbH & Co KG
    Inventors: Gisela Backfisch, Margaretha Henrica Maria Bakker, Günter Blaich, Wilfried Braje, Karla Drescher, Thomas Erhard, Andreas Haupt, Hannes Koolman, Viktor Lakics, Anna Linsenmeier, Helmut Mack, Raimund Peter, Ana Lucia Relo, Xiaona Zhao, Jincheng Wang
  • Patent number: 9540376
    Abstract: The present invention relates to tricyclic hexahydrodiazepinoquinolines, such as compounds of formula (I), carrying a substituted alkyl radical, to a method for producing them, to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HT2C receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-HT2C receptor, to a method for preventing or treating conditions and disorders which respond to the modulation of 5-HT2C receptor, and processes for preparing such compounds and compositions.
    Type: Grant
    Filed: March 13, 2015
    Date of Patent: January 10, 2017
    Assignee: AbbVie Deutschland GmbH & Co. KG
    Inventors: Gisela Backfisch, Margaretha Henrica Maria Bakker, Günter Blaich, Wilfried Braje, Karla Drescher, Thomas Erhard, Andreas Haupt, Viktor Lakics, Anna Linsenmeier, Helmut Mack, Raimund Peter, Ana Lucia Relo, Lynette Smyth
  • Patent number: 9388141
    Abstract: The present invention relates to novel acylaminocycloalkyl compounds, in particular to the compounds of the formula I as described herein and to their salts and N-oxides. The compounds possess valuable therapeutic properties and are suitable, in particular, for treating diseases that respond to modulation of the dopamine D3 receptor.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: July 12, 2016
    Assignees: AbbVie Inc., AbbVie Deutschland GmbH & Co. KG
    Inventors: Andreas Haupt, Jürgen Dinges, Liliane Unger, Karsten Wicke, Robert Van Waterschoot, Karla Drescher, Ana Relo
  • Patent number: 9388148
    Abstract: The present invention relates to novel acylaminocycloalkyl compounds, in particular to the compounds of the formula I as described herein and to their salts and N-oxides. The compounds possess valuable therapeutic properties and are suitable, in particular, for treating diseases that respond to modulation of the dopamine D3 receptor.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: July 12, 2016
    Assignees: AbbVie Inc., AbbVie Deutschland GmbH & Co. KG
    Inventors: Andreas Haupt, Jürgen Dinges, Liliane Unger, Karsten Wicke, Robert Van Waterschoot, Karla Drescher, Ana Relo
  • Patent number: 9376396
    Abstract: The present invention relates to novel acylaminocycloalkyl compounds, in particular to the compounds of the formula I as described herein and to their salts and N-oxides. The compounds possess valuable therapeutic properties and are suitable, in particular, for treating diseases that respond to modulation of the dopamine D3 receptor.
    Type: Grant
    Filed: October 11, 2013
    Date of Patent: June 28, 2016
    Assignees: ABBVIE DEUTSCHLAND GMBH & CO. KG, ABBVIE INC.
    Inventors: Andreas Haupt, Jürgen Dinges, Liliane Unger, Karsten Wicke, Robert van Waterschoot, Scott Mittelstadt, Karla Drescher, Ana Relo
  • Publication number: 20160016954
    Abstract: The present invention relates to tricyclic quinoline and quinoxaline derivatives, to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HT2C receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-HT2C receptor, and to a method for preventing or treating conditions and disorders which respond to the modulation of 5-HT2C receptor.
    Type: Application
    Filed: September 29, 2015
    Publication date: January 21, 2016
    Inventors: Hannes Koolman, Wilfried Braje, Helmut Mack, Andreas Haupt, Ana Lucia Relo, Karla Drescher, Margaretha Henrica Maria Bakker, Viktor Lakics, Carolin Hoft
  • Patent number: 9169253
    Abstract: The present invention relates to tricyclic quinoline and quinoxaline derivatives, to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HT2C receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-HT2C receptor, and to a method for preventing or treating conditions and disorders which respond to the modulation of 5-HT2C receptor.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: October 27, 2015
    Assignee: AbbVie Deutschland GmbH & Co. KG
    Inventors: Hannes Koolman, Wilfried Braje, Helmut Mack, Andreas Haupt, Ana Lucia Relo, Karla Drescher, Margaretha Henrica Maria Bakker, Viktor Lakics, Carolin Hoft
  • Publication number: 20150259346
    Abstract: The present invention relates to tricyclic hexahydrodiazepinoquinolines carrying a substituted alkyl radical, to a method for producing them, to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HT2C receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-HT2C receptor, to a method for preventing or treating conditions and disorders which respond to the modulation of 5-HT2C receptor, and processes for preparing such compounds and compositions.
    Type: Application
    Filed: March 13, 2015
    Publication date: September 17, 2015
    Inventors: Gisela BACKFISCH, Margaretha Henrica Maria BAKKER, Günter BLAICH, Wilfried BRAJE, Karla DRESCHER, Thomas ERHARD, Andreas HAUPT, Viktor LAKICS, Anna LINSENMEIER, Helmut MACK, Raimund PETER, Ana Lucia RELO, Lynette SMYTH
  • Publication number: 20150259343
    Abstract: The present invention relates to tricyclic hexahydrodiazepinoquinolines carrying a cyclic substituent, to a method for producing them, to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HT2C receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-HT2C receptor, to a method for preventing or treating conditions and disorders which respond to the modulation of 5-HT2C receptor, and processes for preparing such compounds and compositions.
    Type: Application
    Filed: March 13, 2015
    Publication date: September 17, 2015
    Inventors: Gisela BACKFISCH, Margaretha Henrica Maria BAKKER, Günter BLAICH, Wilfried BRAJE, Karla DRESCHER, Thomas ERHARD, Andreas HAUPT, Hannes KOOLMAN, Viktor LAKICS, Anna LINSENMEIER, Helmut MACK, Raimund PETER, Ana Lucia RELO